216 related articles for article (PubMed ID: 1294735)
1. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone.
Pincus T; Marcum SB; Callahan LF
J Rheumatol; 1992 Dec; 19(12):1885-94. PubMed ID: 1294735
[TBL] [Abstract][Full Text] [Related]
2. Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.
Pincus T; Callahan LF
Agents Actions Suppl; 1993; 44():67-75. PubMed ID: 8103964
[TBL] [Abstract][Full Text] [Related]
3. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal antiinflammatory drugs.
Pincus T; Marcum SB; Callahan LF; Adams RF; Barber J; Barth WF; Gordon GV; Huston JW; Polk JR; Whelton JC
J Rheumatol; 1992 Dec; 19(12):1874-84. PubMed ID: 1294734
[TBL] [Abstract][Full Text] [Related]
4. Longterm combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX) and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy.
Rau R; Schleusser B; Herborn G; Karger T
J Rheumatol; 1998 Aug; 25(8):1485-92. PubMed ID: 9712088
[TBL] [Abstract][Full Text] [Related]
5. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis.
Singh G; Fries JF; Williams CA; Zatarain E; Spitz P; Bloch DA
J Rheumatol; 1991 Feb; 18(2):188-94. PubMed ID: 1673721
[TBL] [Abstract][Full Text] [Related]
6. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
Sokka T; Pincus T
J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
[TBL] [Abstract][Full Text] [Related]
7. Differences in the use of second-line agents and prednisone for treatment of rheumatoid arthritis by rheumatologists and non-rheumatologists.
Criswell LA; Such CL; Yelin EH
J Rheumatol; 1997 Dec; 24(12):2283-90. PubMed ID: 9415629
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate, hydroxychloroquine, and intramuscular gold in rheumatoid arthritis: relative area under the curve effectiveness and sequence effects.
Hurst S; Kallan MJ; Wolfe FJ; Fries JF; Albert DA
J Rheumatol; 2002 Aug; 29(8):1639-45. PubMed ID: 12180722
[TBL] [Abstract][Full Text] [Related]
9. Slow-acting anti-rheumatic drug therapy for rheumatoid arthritis.
Clegg DO; Ward JR
Nurse Pract; 1987 Mar; 12(3):44, 49-52. PubMed ID: 2882451
[TBL] [Abstract][Full Text] [Related]
10. What explains the variation among rheumatologists in their use of prednisone and second line agents for the treatment of rheumatoid arthritis?
Criswell LA; Henke CJ
J Rheumatol; 1995 May; 22(5):829-35. PubMed ID: 8587068
[TBL] [Abstract][Full Text] [Related]
11. Longterm methotrexate use in rheumatoid arthritis: 12 year followup of 460 patients treated in community practice.
Wluka A; Buchbinder R; Mylvaganam A; Hall S; Harkness A; Lewis D; Littlejohn GO; Miller MH; Ryan PF
J Rheumatol; 2000 Aug; 27(8):1864-71. PubMed ID: 10955325
[TBL] [Abstract][Full Text] [Related]
12. Slow acting anti-rheumatic drugs in the treatment of rheumatoid arthritis.
Kovarsky J
Tex Med; 1985 Sep; 81(9):35-9. PubMed ID: 3931276
[No Abstract] [Full Text] [Related]
13. Disappointing longterm results with disease modifying antirheumatic drugs. A practice based study.
Galindo-Rodriguez G; Aviña-Zubieta JA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1999 Nov; 26(11):2337-43. PubMed ID: 10555887
[TBL] [Abstract][Full Text] [Related]
14. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis.
Galindo-Rodriguez G; Avina-Zubieta JA; Fitzgerald A; LeClerq SA; Russell AS; Suarez-Almazor ME
J Rheumatol; 1997 Apr; 24(4):633-8. PubMed ID: 9101493
[TBL] [Abstract][Full Text] [Related]
15. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a longterm observational study.
Papadopoulos NG; Alamanos Y; Papadopoulos IA; Tsifetaki N; Voulgari PV; Drosos AA
J Rheumatol; 2002 Feb; 29(2):261-6. PubMed ID: 11838843
[TBL] [Abstract][Full Text] [Related]
16. Drugs for rheumatoid arthritis.
Med Lett Drugs Ther; 1989 Jun; 31(795):61-4. PubMed ID: 2567489
[No Abstract] [Full Text] [Related]
17. Rheumatoid arthritis: a pharmacologic overview.
Pinals RS
Am Fam Physician; 1988 Mar; 37(3):145-52. PubMed ID: 2894754
[TBL] [Abstract][Full Text] [Related]
18. Longterm methotrexate therapy in rheumatoid arthritis: a review.
Kremer JM
J Rheumatol Suppl; 1985 Dec; 12 Suppl 12():25-8. PubMed ID: 3913773
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
20. [Long-term drug therapy in inflammatory rheumatic diseases using chronic polyarthritis as an example. 2. Basic principles of long-term drug therapy: choice of optimal therapeutic agents].
Menninger H; Burkhardt H
Fortschr Med; 1983 Apr; 101(14):639-45. PubMed ID: 6406333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
